10-KPeriod: FY2019

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2019

Filed February 24, 2020For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) filed its 2019 10-K on February 24, 2020, detailing its financial performance and strategic direction for the year ending December 30, 2019. A significant event during 2019 was the completion of the acquisition of Celgene, which is expected to be a transformative event for the company, bringing a strong portfolio of products in oncology and other therapeutic areas. This acquisition, along with ongoing research and development efforts, is central to BMY's future growth strategy. Investors should note the company's focus on integrating the Celgene business and realizing synergies, as well as managing the debt incurred to finance the acquisition. The report outlines various risks, including those related to the pharmaceutical industry's regulatory environment, competition, and intellectual property, as well as the successful commercialization of new products and the performance of existing blockbuster drugs. The company's ability to navigate these factors will be crucial for its long-term success.

Financial Highlights

57 data points
Beta

Revenue

$26.14B

69.1% Gross Margin

Net Income

$3.44B

13.2% Net Margin

EPS (Diluted)

$2.01

Total Assets

$129.94B

Cash & Equivalents

$12.35B

Free Cash Flow

$7.37B

Financial Statements
Beta
Revenue$26.14B
Cost of Revenue$8.08B
Gross Profit$18.07B
R&D Expenses$6.15B
SG&A Expenses$4.87B
Operating Expenses$21.17B
Interest Expense$656.00M
Net Income$3.44B
EPS (Basic)$2.02
EPS (Diluted)$2.01
Shares Outstanding (Basic)1.71B
Shares Outstanding (Diluted)1.71B

Key Highlights

  • 1Completion of the transformative acquisition of Celgene in the fourth quarter of 2019.
  • 2Significant investment in research and development (R&D) to drive future growth, with a focus on oncology, immunology, and cardiovascular diseases.
  • 3The company's portfolio is underpinned by key products such as Eliquis, Opdivo, and Revlimid (acquired through Celgene).
  • 4Management's discussion and analysis (MD&A) likely details the strategic rationale and expected impact of the Celgene acquisition, including integration plans and synergy realization.
  • 5The filing addresses various risks inherent in the pharmaceutical industry, including regulatory changes, patent expirations, competition, and pricing pressures.
  • 6BMY is committed to managing its capital structure effectively, particularly in light of the debt financing for the Celgene acquisition.

Frequently Asked Questions

The most significant event was the completion of the acquisition of Celgene Corporation in November 2019. This acquisition was intended to significantly expand BMY's product portfolio and R&D pipeline, particularly in oncology and immunology.

The acquisition of Celgene was financed through a combination of cash and debt. This likely resulted in a substantial increase in BMY's total debt and altered its capital structure. The filing's financial statements and MD&A would provide details on the balance sheet impact and financing costs.

The filing highlights BMY's focus on oncology, immunology, and cardiovascular diseases. Key products include Eliquis and Opdivo. Following the Celgene acquisition, Revlimid became a significant product within the company's portfolio.

Key risks include the success of integrating the Celgene acquisition, the ability to achieve projected synergies, competition from other pharmaceutical companies, patent expirations for key drugs, government regulation and pricing pressures, and the outcome of ongoing legal proceedings and R&D failures.